ConductScience.org, home

Paper41544372

Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic.

Rosenberg A and 9 others. J Prev Alzheimers Dis, 2026. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic. Papers, record 41544372. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41544372

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic.
PubMed
Journal
J Prev Alzheimers Dis
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
4.39, provisional
iCite
Revised in PubMed
2026-06-26
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rosenberg AAnna
2Solomon AAlina
3Bonnard AAlexandre
4Daniilidou MMakrina
5Hagman GGöran
6Hall AAnette
7Matton AAnna
8Öhlund-Wistbacka UUlf
9Westman EEric
10Kivipelto MMiia

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Alzheimer DiseaseMajor topic
Eligibility DeterminationMajor topic
Antibodies, MonoclonalMajor topic
Amyloid beta-PeptidesMajor topic
Humans
Sweden
Female
Male
Aged
Apolipoprotein E4
Aged, 80 and over
Antibodies, Monoclonal, Humanized

Source PubMed

Download CSV of topics

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42898005Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.Eur J Neurol2026https://conductscience.org/library/papers/42898005PubMed
42874425Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France.J Prev Alzheimers Dis2026https://conductscience.org/library/papers/42874425PubMed
42824080Cerebral microbleed assessment on MRI in a memory clinic: Reliability, prevalence, and implications for anti-amyloid therapy.Alzheimers Dement (Amst)2026https://conductscience.org/library/papers/42824080PubMed
42729372Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series.Front Psychiatry2026https://conductscience.org/library/papers/42729372PubMed
42538752Biomarker-Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease-Modifying Treatments: A Consensus Statement by Belgian Experts.Eur J Neurol2026https://conductscience.org/library/papers/42538752PubMed
42426363Defining and Measuring Cognitive Decline and Clinical Relevance.Neurol Ther2026https://conductscience.org/library/papers/42426363PubMed
42306480Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis.JAR Life2026https://conductscience.org/library/papers/42306480PubMed
41722234Low number of patients qualifying for amyloid targeting immunotherapy.J Prev Alzheimers Dis2026https://conductscience.org/library/papers/41722234PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APOE348PubTator's text mininghttps://conductscience.org/library/genes/348NCBI Gene
APP351PubTator's text mininghttps://conductscience.org/library/genes/351NCBI Gene
MAPT4137PubTator's text mininghttps://conductscience.org/library/genes/4137NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41544372

GET https://conductscience.org/api/papers/v1/41544372/authors